Our results indicate that MAPK3 emerges as a promising target for Glycyrrhizin in AP therapy, and maintaining the expression of MAPK3 in acinar cells to ameliorate cell necrosis could represent a novel and potential therapeutic strategy for AP treatment. This evidence concerns the gene MAPK3 and alkaline phosphatase measurement.